Optimal size threshold for PIRADSv2 category 5 upgrade and its positive predictive value: is it predictive of “very high” likelihood of clinically-significant cancer?
Vishal Batheja(George Washington University), Shawn Haji-Momenian(Washington University Medical Center), Michael K. Wynne(George Washington University), Michael J. Whalen(George Washington University), Mohamed Osman(Cornell University), George Morcos(George Washington University), Byung‐Cheul Shin(Pusan National University), Jonathan W. Riess(University of California Davis Medical Center), Dmitry Nemirovsky(George Washington University)
Cited by 2
Related Papers
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|805
siRNA-directed inhibition of HIV-1 infection
|Nature Medicine|2002|777
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|670